Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
3 Biotech Stocks to Buy for Long-Term Gains
07:01am, Thursday, 13'th Jul 2023
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated
Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?
11:05am, Wednesday, 12'th Jul 2023
Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.
Pfizer Just Invested $25 million In This Biotech
09:59am, Friday, 07'th Jul 2023
Shares of Caribou Biosciences NASDAQ: CRBU were up 45% yesterday after Pfizer NYSE: PFE made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million shares of C
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
09:23am, Friday, 07'th Jul 2023
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?
08:37am, Friday, 07'th Jul 2023
Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could b
3 Stocks Moving Today: CRBU, META, AFRM
02:52pm, Thursday, 06'th Jul 2023
Here are three of today's notable movers, as the broader market takes a tumble following this morning's flood of economic data.
Why Shares of Caribou Biosciences Are Skyrocketing Today
11:54am, Thursday, 06'th Jul 2023
Caribou is a clinical-stage biotech that specializes in CRISPR gene-editing therapies. Caribou said it had $291 million in cash at the end of the first quarter.
The $25 Million Reason Caribou Biosciences (CRBU) Stock Is Soaring Today
11:52am, Thursday, 06'th Jul 2023
Caribou Biosciences (NASDAQ: CRBU ) stock is taking off on Thursday after the gene-editing company announced an investment from Pfizer (NYSE: PFE ). Caribou Biosciences reports that Pfizer has made a
Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium
08:19am, Thursday, 06'th Jul 2023
Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 31'st May 2023
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates
06:20pm, Tuesday, 09'th May 2023
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.35 per share a year ago.
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:00pm, Monday, 01'st May 2023
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates
08:35pm, Thursday, 09'th Mar 2023
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
There's a Lot of Upside For Emerging Gene-Editing Companies
09:16am, Tuesday, 21'st Feb 2023
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter
Caribou: Potential To Improve Response Duration With Higher Dose Level
07:12am, Tuesday, 24'th Jan 2023
Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with relapsed/refractory B-cell NHL. Additional results from the phase 1 ANTLER
